ReviewInternational journal of nanomedicine2026
Therapeutic Opportunities for Macrophage Targeted Nanomedicine in Diabetes Mellitus.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a common metabolic disease affecting more than 500 million people worldwide. Macrophages, driving inflammation, immune dysregulation, and tissue injury, contribute to diabetes progression and diabetic complications. Nanomedicine offers unique advantages in drug delivery, tissue accumulation, and macrophage targeting, making it particularly suitable for modulating macrophage-mediated pathological processes in diabetes. In this review, we describe the role of macrophages in the pathological progression of diabetes mellitus and further summarize current strategies for using nanoparticles to target macrophages. We highlight the diagnostic and therapeutic potential of macrophage-targeted nanoparticles in diabetes and its related complications. Finally, we discuss key translational challenges, including biodistribution, off-target uptake, long-term immunological safety, toxicity, and clinical applicability. This review provides a distinct framework for understanding how macrophage-targeted nanomedicine can be developed to improve diabetes diagnosis, therapeutic modulation, and the management of diabetic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.